Issue of Share Options

RNS Number : 7902I
Diaceutics PLC
06 April 2020
 

Diaceutics PLC

("Diaceutics" or the "Company")

 

Issue of Share Options

 

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issuance of share options over ordinary shares of 0.2p each in the Company ("Share Options") to certain Directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP") established at the time of the Company's admission to AIM. These awards are made in accordance with the Company's long term incentive plan.

 

Share Options were granted as follows:

 

Name

Number of Share Options granted

Total no. of ordinary shares under option post grant

% of existing issued share capital

Grant date

Peter Keeling, CEO

180,000

180,000

0.26%

3 April 2020

Philip White CFO

180,000

180,000

0.26%

3 April 2020

Ryan Keeling CIO

180,000

180,000

0.26%

3 April 2020

Damian Thornton COO and PDMR

94,304

98,504

0.14%

3 April 2020

Jordan Clark CCO and PDMR

67,714

71,914

0.10%

3 April 2020

Susanne Munksted PDMR

62,272

66,472

0.10%

3 April 2020

Other employees (72 persons with no individual in excess of 45,000 Share Options)

665,955

825,555

1.19%

No later than 20 April 2020

 

 

The Share Options vest in full after three years following date of grant. The exercise price of the Share Options is 126.5p per share which has been calculated by using the average mid-market closing price over the past five business days.

 

Following the grant the total number of share options outstanding is 1,602,444, representing approximately 2.3% of the Company's current issued share capital of 69,583,100.

 

 

Enquiries:

 

Diaceutics PLC

www.diaceutics.com

Peter Keeling, Chief Executive Officer

via Walbrook PR

Philip White, Chief Financial Officer

 

 

 

Cenkos Securities plc (Nominated adviser and broker)

+44 (0)20 7397 8900

Callum Davidson / Giles Balleny

 

Michael Johnson (Sales)

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

       

 

 

 

About Diaceutics

Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing.  By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Peter Keeling

2

Reason for notification

 

a.

Position/Status

Chief Executive Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2 p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 126.5p per share

180,000

 

 

 

e.

Date of the transaction

3 April 2020

f.

Place of the transaction

Outside a trading venue

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Philip White

2

Reason for notification

 

a.

Position/Status

Chief Financial Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2 p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 126.5p per share

180,000

 

 

 

e.

Date of the transaction

3 April 2020

f.

Place of the transaction

Outside a trading venue

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Ryan Keeling

2

Reason for notification

 

a.

Position/Status

Chief Information Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2 p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 126.5p per share

180,000

 

 

 

e.

Date of the transaction

3 April 2020

f.

Place of the transaction

Outside a trading venue

 

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Damian Thornton

2

Reason for notification

 

a.

Position/Status

Chief Operating Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2 p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 126.5p per share

94,304

 

 

 

e.

Date of the transaction

3 April 2020

f.

Place of the transaction

Outside a trading venue

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jordan Clark

2

Reason for notification

 

a.

Position/Status

Chief Technology Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2 p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 126.5p per share

67,714

 

 

 

e.

Date of the transaction

3 April 2020

f.

Place of the transaction

Outside a trading venue

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Susanne Munksted

2

Reason for notification

 

a.

Position/Status

Managing Director and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2 p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 126.5p per share

62,272

 

 

 

e.

Date of the transaction

3 April 2020

f.

Place of the transaction

Outside a trading venue

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHZZGGDDFVGGZM

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings